stockrowAptarGroup, Inc.
ATR Healthcare Medical Instruments & Supplies
AptarGroup, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.8 billion, up 5.42% from fiscal 2024.
- Revenue
- +6.03%
- EPS
- −73.9%
- Free cash flow
- −16.9%
- Total debt
- +14.6%
Quarter to September 2026, against a year earlier
Follow ATR
Alert me
AptarGroup, Inc. (ATR) EPS (diluted)
AptarGroup, Inc.'s EPS (diluted) for fiscal 2025 was $5.89, up 6.51% from $5.53 in fiscal 2024. Over the twelve months to 30 September 2026 it was $4.12. Over the past ten years it has ranged from $3.00 (fiscal 2018) to $5.89 (fiscal 2025) — the current reading is the highest in ten years. EPS (diluted) has risen for 3 consecutive fiscal years. AptarGroup, Inc. ranks 5th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $5.89 | 6.51% |
| FY2024 | $5.53 | 30.12% |
| FY2023 | $4.25 | 18.38% |
| FY2022 | $3.59 | (0.55%) |
| FY2021 | $3.61 | 12.46% |
| FY2020 | $3.21 | (12.30%) |
| FY2019 | $3.66 | 22.00% |
| FY2018 | $3.00 | (12.02%) |
| FY2017 | $3.41 | 7.57% |
| FY2016 | $3.17 | 2.59% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.51 | (62.50%) |
| Jun 2026 | $1.36 | 21.43% |
| Mar 2026 | $1.12 | (0.88%) |
| Dec 2025 | $1.13 | (41.15%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ALGN Align Technology, Inc. compare | $6.87 |
| ATR AptarGroup, Inc. | $4.12 |
| COO The Cooper Companies, Inc. compare | $2.93 |
| SOLV Solventum Corporation compare | $0.89 |
| AVTR Avantor, Inc. compare | $0.50 |
| RGEN Repligen Corporation compare | −$0.21 |
| BLCO Bausch + Lomb Corporation compare | −$0.30 |
| BAX Baxter International Inc. compare | −$1.41 |
| TFX Teleflex Incorporated compare | −$23.29 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on ATR
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement